141 related articles for article (PubMed ID: 12597149)
1. Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats.
Esmat AY; Refaie FM; Shaheen MH; Said MM
Tumori; 2002; 88(6):513-21. PubMed ID: 12597149
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
Kadmon D
J Cell Biochem Suppl; 1992; 16H():122-7. PubMed ID: 1289667
[TBL] [Abstract][Full Text] [Related]
4. Alpha-difluoromethylornithine inhibits N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in zinc-deficient rats: effects on esophageal cell proliferation and apoptosis.
Fong LY; Pegg AE; Magee PN
Cancer Res; 1998 Dec; 58(23):5380-8. PubMed ID: 9850069
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
6. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
7. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Simoneau AR; Gerner EW; Nagle R; Ziogas A; Fujikawa-Brooks S; Yerushalmi H; Ahlering TE; Lieberman R; McLaren CE; Anton-Culver H; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):292-9. PubMed ID: 18268112
[TBL] [Abstract][Full Text] [Related]
8. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
9. The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial.
Brawley OW; Thompson IM
Cancer Treat Res; 1996; 88():189-200. PubMed ID: 9239480
[No Abstract] [Full Text] [Related]
10. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
[TBL] [Abstract][Full Text] [Related]
11. 2-Deoxy-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo.
Saydjari R; Upp JR; Alexander RW; Barranco SC; Townsend CM; Thompson JC
Invest New Drugs; 1989 Jul; 7(2-3):131-8. PubMed ID: 2507471
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.
Rao KV; Johnson WD; Bosland MC; Lubet RA; Steele VE; Kelloff GJ; McCormick DL
Cancer Res; 1999 Jul; 59(13):3084-9. PubMed ID: 10397249
[TBL] [Abstract][Full Text] [Related]
13. The potential application of finasteride for chemoprevention of prostate cancer.
Gormley GJ; Brawley O; Thompson I
Ann N Y Acad Sci; 1995 Sep; 768():163-9. PubMed ID: 8526345
[No Abstract] [Full Text] [Related]
14. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of deoxyribonucleic acid synthesis by difluoromethylornithine. Role of polyamine metabolism in monocrotaline-induced pulmonary hypertension.
Hacker AD
Biochem Pharmacol; 1992 Sep; 44(5):965-71. PubMed ID: 1530663
[TBL] [Abstract][Full Text] [Related]
16. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
17. Chemopreventive effects of zinc on prostate carcinogenesis induced by N-methyl-N-nitrosourea and testosterone in adult male Sprague-Dawley rats.
Banudevi S; Elumalai P; Arunkumar R; Senthilkumar K; Gunadharini DN; Sharmila G; Arunakaran J
J Cancer Res Clin Oncol; 2011 Apr; 137(4):677-86. PubMed ID: 20552224
[TBL] [Abstract][Full Text] [Related]
18. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
19. Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.
Janakiram NB; Mohammed A; Bryant T; Zhang Y; Brewer M; Duff A; Biddick L; Singh A; Lightfoot S; Steele VE; Rao CV
Sci Rep; 2016 Nov; 6():37046. PubMed ID: 27841323
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
